{"name":"Shanghai United Cell Biotechnology Co., Ltd","slug":"shanghai-united-cell-biotechnology-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuwJBVV95cUxNQWYwbGQtWnN1TmNuZDYxN0lySS1NSGFzU2pPT3VlangtdnloUnhrUDZsRk5ZSGFNVnhmdm01bmhUMDJCTkpkZXUwNmkxQWREWUk0TFowOWpjQmRXd0R1ajYzX1MzOU5ZUmdHbmdjSU9KVlNpNjdBUDFKbWtvODNPN3JRZXoxUllRN0daSWVxVzhWbmpHaUp6bkxRY3MzY2tWSzlFRjd0ZktuU2sxWTk5SkVCZkpSa0ROeGhKSzdNQnZVdzJxMG1sVWs4MVMxVEU3YzZ4c3RpMFFzYkhGTjh5d1VGRXZ1NFVSTjZjcGkxM3JCeEU4SnpuTnlGaWpqNEFtZFVFSkdnalJkTGI0djluU2xFSDNkTDVKUmVkQXpHSmluVXJIeW01YTdZVWtFaVpTRFY4WEVoYUtHRWc?oc=5","date":"2026-02-04","type":"pipeline","source":"PR Newswire","summary":"Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer - PR Newswire","headline":"Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQSDBXZ243SnRELU9tTG5VZTBBaUFIQkVwVmJEYW42OGc5emVxOWVhSGlZcng5U1RDZE5IWUM5YUdYRE1VSDBpVFZxTW5iNUF0X29DSUlDa3RBaHpKRmhwODNuU1hlRmEyQzNDLU9VUlVYN29vb3dTZFl1T21FU2FWNXpGZklzS2hZQXNoV21KczXSAZYBQVVfeXFMTmdVSG5xdU5Qa2JKdFpoQWYyaHhkUkxfM1FUdmljWjc5Z2VZYkxxRzhsa0VmZWZXc2h1UWY4MFFibXlwbXplT0VBS2dITk5ya1oxVlRwN3JJUF9fOFkwQlZ5eHB1NmNwRWZQV0NvMVlmSDZka3laZlZTMjNaN1FXdWxiU0hUSC1XckpWb09qRGNVSDI3UXdR?oc=5","date":"2026-01-17","type":"pipeline","source":"BioInformant","summary":"CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide - BioInformant","headline":"CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxNdGNDalNzNTNYcWpEd2VjeFNHcVo1UVdfeTJZSHE0VzJZZkRqekIxcVJaOGFHa0l4Z0d5QkFYeVAteE55Yi1ud3JTQkFOcktNTklONmV0UnI5bzU2c2ZJUU81OFRpQUJBeDFaZlZfbWVfZ2ttcUpQQl94MllaRDFtMXZR?oc=5","date":"2025-10-11","type":"pipeline","source":"China Daily - Global Edition","summary":"Shanghai impresses global biotech, pharma markets with quality growth - China Daily - Global Edition","headline":"Shanghai impresses global biotech, pharma markets with quality growth - China Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxOTFRWdk1faWotclNmbkphcC1XeHJ0R0s0UnkyYnF6LVBrQjEycDZJSERQZnk4ZktwUTBHbG1wVTFSU1FxOHVTWUx3WTFnd2I3VlpnWDVEbUVEU05NN29zWlA3ZkFkMWU3YmotRno2S29NdUhWRTJadnc3SzFacVhnTjRwODJENnZXYVh4QzYxSjIwMG4zMnNjaG94VXdRellLZW5PbkpwTnY5RGl3VTlpUW5jYmtDb09iTTg5RHQ0ZG9tTDl0Zk1GQV9nS1R5WUxsOXpkeWtRcURYVEJvQ0dmNnZZSXlYUnBobk1PYw?oc=5","date":"2025-10-06","type":"pipeline","source":"PR Newswire","summary":"Lupus Nephritis Market to Advance at a CAGR of 8.5% During the Forecast Period (2025-2034) | DelveInsight - PR Newswire","headline":"Lupus Nephritis Market to Advance at a CAGR of 8.5% During the Forecast Period (2025-2034) | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxOS2RGakEtZVoyYmVlY054WEVQYWpRS3dON2JaNGZRMEtkNTJTUkJLVm5TRHc1cTZtRUhReF9lcGVJY0ZLR1VfeHFzY2l2dC1MSEdLYWRGMzVHM092LVlFaUVvSnEzbG9FNlIyeUhpa0tNME8xZGVQT3VUVFJzbGo5QzFxMW9iTjRrYlF0bzd6S3RXVUxQY01nM0JidGRFdWFERW9ZYzl3blV3TFFuQkpVLVI1X01HdGczZjNpQ0JCeTgyQVNQLVdIUA?oc=5","date":"2025-06-03","type":"pipeline","source":"BioPharma APAC","summary":"XellSmart Advances Global Leadership in iPSC-Derived Cell Therapies for CNS Disorders - BioPharma APAC","headline":"XellSmart Advances Global Leadership in iPSC-Derived Cell Therapies for CNS Disorders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxNZThaVC01a01fMEVoQnloNVRDYTlmdm01M2ZIRFQ3Q2FzbUxTblBIbHRIY1lXVzBjazVJN3BaMHFLcDVwMzRvWVBiYlNWMUVzSmJQWjlLOHU3d1hrUFh1clRFMkdTakoxSzdBQ3FOdlMtSjRocEJjNGx4a2I3U3ZYaEVlMy02TG9icHdoOEdCTTZFUXNIOWxwNzd4ajhDaUQtSzBiU1EtdlRWaUxFaHk0bEo1OFQwWU42NFE3YTQwbzl0XzY4TW5PbElsZWlmOTNy?oc=5","date":"2025-05-26","type":"trial","source":"BioPharma APAC","summary":"UniXell Biotech Initiates China’s First iPSC-Based Cell Therapy Trial for Parkinson’s Disease - BioPharma APAC","headline":"UniXell Biotech Initiates China’s First iPSC-Based Cell Therapy Trial for Parkinson’s Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE01WDZUTnJ1aF9Udk9IWmhVQmFZajBDdHVDU2I5SEQ5QmdLZFk5blhCaXlXWE1MYlptM19WWDVZdDlFNVRsNVZNZkQyMDV0cFhid1huY1BvT01hNVZtRU11WGhB?oc=5","date":"2024-12-12","type":"pipeline","source":"Global Times","summary":"Bayer Co.Lab welcomes three new resident companies in China - Global Times","headline":"Bayer Co.Lab welcomes three new resident companies in China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQZ0gxNEVCQjFsYmpLdTRPWHU5LTB6TEl2VFhlNi1famIteUlNNDR5cFowMExYeEJPb1lVNjh5UWlQQTJsMDVZVnMwRklIWkxUbmpsQmFaZmozZ3BJcXcteERJVk1ZWkdPTnZYZ0VUejJMTVZJSEh0d2VKSkk1R2ZxSFBRMUNtWmgwXy1CUVhuV2xjRFBoQmFyUHFJa1hxYVJVRXB3anN5a1c3ZV9fNUItRVNNREpDU2NLeXc?oc=5","date":"2024-10-31","type":"pipeline","source":"Reuters","summary":"How Asian pharma suppliers cash in on Ozempic copies - Reuters","headline":"How Asian pharma suppliers cash in on Ozempic copies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE9xMFdNdzJDYkx3d091dTh1dmk2bjlKQnZ4QVQwb0J4N1UxZ0lDbmJHdk0tS3JzNTNJMXMzaDBBd2FYQXl2UjlCRk5tZGZ5QWdxRDh4UmdnMjBSbDBlSVcybQ?oc=5","date":"2023-09-12","type":"deal","source":"复宏汉霖","summary":"Henlius Expands Collaboration with KGbio to Develop, Commercialize and Supply Henlius' novel anti-PD-1 mAb HANSIZHUANG in MENA-Media - 复宏汉霖","headline":"Henlius Expands Collaboration with KGbio to Develop, Commercialize and Supply Henlius' novel anti-PD-1 mAb HANSIZHUANG i","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPWE9rSmRHS1kzLTAyV0pPaXU2QXdGM3czRnVITUhlZWtRMzNObC12SGhtUnlBVGt5TWhOSFFtdTNHenJIX0sxRjh0VTJjb2FMVGxiM21SZzlIaThCRG5oQUdTeUxkdEdpYW0tekl2amVuQVY5NEdGMDRzb2s5aHZxQVd1WkE2aGpIZFpRa0xqSjVpOTRFSkFaM1dpTGR5emNDanpoVldSbw?oc=5","date":"2023-07-18","type":"regulatory","source":"BioSpace","summary":"Yikaida CAR-T Cell Therapy Approved as a Second-line Therapy for New Indication - BioSpace","headline":"Yikaida CAR-T Cell Therapy Approved as a Second-line Therapy for New Indication","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOdmVSV09GRUw2MG1zN2pHYUxaNGhrUHdpR2IzN2RLbllUOUdtUW5SX0xBOWRWZmJMNl90cXBMQmlRc2JUaDlMX2xDYk1XR3JiZFY5VlpxdUw5aW9VMU9xS0RuSUJNc0kxQTMwRjdPOG5nNnIxS0hJMVkzZ1JNMV9HZ2h4UjhKWlFCOUlQWkRkS2JGMVdDcEZXSThTSWZ4M2hS?oc=5","date":"2021-06-24","type":"regulatory","source":"Sixth Tone","summary":"China Approves First CAR T-Cell Therapy for Cancer Patients - Sixth Tone","headline":"China Approves First CAR T-Cell Therapy for Cancer Patients","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE5NWUxzRjBRZ3hqWnJwV1BpT1g4UmtzSTFZZy1CYzFNVVN2STNQeEpzNWtyTXpYUU5ZeG1PSWVmdWtxOFlsQlE4T0dfZkc5bm9pZVdudw?oc=5","date":"2018-01-26","type":"pipeline","source":"nature.com","summary":"Chinese health biotech and the billion-patient market - nature.com","headline":"Chinese health biotech and the billion-patient market","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}